1. Home
  2. STK vs APMD Comparison

STK vs APMD Comparison

Compare STK & APMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Columbia Seligman Premium Technology Growth Fund Inc

STK

Columbia Seligman Premium Technology Growth Fund Inc

N/A

Current Price

$46.36

Market Cap

921.0M

Sector

Finance

ML Signal

N/A

Logo Apnimed Inc. Common Stock

APMD

Apnimed Inc. Common Stock

N/A

Current Price

$18.73

Market Cap

895.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
STK
APMD
Founded
N/A
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
921.0M
895.5M
IPO Year
2009
2026

Fundamental Metrics

Financial Performance
Metric
STK
APMD
Price
$46.36
$18.73
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $50.00
AVG Volume (30 Days)
48.9K
★ 367.8K
Earning Date
01-01-0001
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
★ 9.63
Revenue
N/A
N/A
Revenue This Year
N/A
$158.34
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$1.85
Revenue Growth
N/A
N/A
52 Week Low
$32.50
$13.88
52 Week High
$58.46
$35.29

Technical Indicators

Market Signals
Indicator
STK
APMD
Relative Strength Index (RSI) 34.31 55.41
Support Level $38.43 $16.43
Resistance Level $53.92 $19.83
Average True Range (ATR) 1.86 1.48
MACD -0.40 0.50
Stochastic Oscillator 6.35 93.63

Price Performance

Historical Comparison
STK
APMD

About STK Columbia Seligman Premium Technology Growth Fund Inc

Columbia Seligman Premium Technology Growth Fund Inc is a closed-end management investment company. Its investment objective is to seek growth of capital and current income. The fund invests in various sectors such as consumer discretionary, industrials, information technology and telecommunication services.

About APMD Apnimed Inc. Common Stock

Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).

Share on Social Networks: